Table 3. Gene expression of SMC and EC lineage genes in cultured SMPCs.

Gene name	Type 2 diabetes without MVD	Type 2 diabetes with PAD	Type 2 diabetes with CAD	Healthy control	Non-type 2 diabetes with PAD	Non-Type 2 diabetes with CAD	p-value
SMC							
ACTA2	1.0 ± 0.1^{a}	0.9 ± 0.2	$0.4 \pm 0.1\,\Delta$	$1.0 \pm 0.2\,\Delta$	0.6 ± 0.1	0.9 ± 0.3	<0.05
MYH11	2.7 ± 1.0	0.8 ± 0.2	$0.7 \pm 0.2\,\Delta$	$1.0 \pm 0.5\,\Delta$	$0.6 \pm 0.2\,\Delta$	$1.3 \pm 0.4\,\Delta$	NS
SMT	1.5 ± 0.3	1.0 ± 0.1	1.2 ± 0.3	$1.0 \pm 0.2\,\Delta$	1.4 ± 0.3	0.9 ± 0.2	NS
SRF	1.2 ± 0.2	$1.0 \pm 0.01\,\Delta$	$1.2 \pm 0.1\,\Delta$	1.0 ± 0.3	1.3 ± 0.7	1.3 ± 0.2	NS
KLF4	0.8 ± 0.1	0.6 ± 0.1	$0.7 \pm 0.1\,\Delta$	1.0 ± 0.2	$0.5 \pm 0.1\,\Delta$	1.0 ± 0.2	NS
SMAD4	1.0 ± 0.1	0.8 ± 0.1	$0.9 \pm 0.02\,\Delta$	$1.0 \pm 0.2\,\Delta$	$0.8 \pm 0.05\,\Delta$	0.8 ± 0.03	NS
TGFB1	0.8 ± 0.1	0.9 ± 0.1	1.1 ± 0.1	$1.0 \pm 0.2\,\Delta$	$0.8 \pm 0.1\,\Delta$	0.8 ± 0.1	NS
TGFBR1	0.6 ± 0.1	$0.6 \pm 0.05\,\Delta^{b}$	$0.9 \pm 0.1\,\Delta$	$1.0 \pm 0.2\,\Delta$	0.9 ± 0.2	1.0 ± 0.2	<0.05
TGFBR2	0.5 ± 0.1^{c}	0.6 ± 0.03	$0.8 \pm 0.03\,\Delta^{d}$	1.0 ± 0.2	0.8 ± 0.1	0.6 ± 0.1	<0.05
BMP6	$1.0 \pm 0.3\,\Delta$	1.9 ± 0.4^{e}	0.7 ± 0.8	$1.0 \pm 0.2\,\Delta^{f}$	1.0 ± 0.2	$0.4 \pm 0.1\,\Delta$	<0.05
PDGFBB	$0.6 \pm 0.1\,\Delta$	1.2 ± 0.3	$1.2 \pm 0.2\,\Delta$	$1.0 \pm 0.2\,\Delta$	1.5 ± 0.3^{g}	0.8 ± 0.1	<0.05
COL1A1	0.5 ± 0.2	$0.3 \pm 0.1\,\Delta$	0.9 ± 0.3	1.0 ± 0.3	0.4 ± 0.2	0.8 ± 0.3	NS
EC							
KDR	0.3 ± 0.1^{h}	1.5 ± 0.4	0.8 ± 0.2	1.0 ± 0.4	1.4 ± 0.5	1.1 ± 0.5	<0.05
VEGFA	1.2 ± 0.2^{i}	0.7 ± 0.1	1.0 ± 0.1	$1.0 \pm 0.2\,\Delta$	0.8 ± 0.2	1.4 ± 0.3	<0.05
NOS3	0.5 ± 0.1^{j}	0.3 ± 0.05	$0.5 \pm 0.1\,\Delta$	$1.0 \pm 0.1\,\Delta$	0.7 ± 0.3	0.7 ± 0.2	<0.05
PECAM1	$0.5 \pm 0.1\,\Delta^{k}$	0.8 ± 0.1^{l}	$1.0 \pm 0.04\,\Delta^{m}$	$1.0 \pm 0.2\,\Delta$	0.8 ± 0.2	1.0 ± 0.2	<0.05

Data are expressed as relative mRNA expression +/- SEM compared to the healthy control group. N=6 per group unless indicated by Δ (N=5). *ACTA2*, α-Smooth muscle actin; *MYH11*, Smooth muscle myosin heavy chain; *SMT*, Smoothelin, *SRF*, Serum response factor; *KLF4*, Krüppel-like factor 4; *SMAD4*; Mothers against decapentaplegic homolog 4; *TGFB1*, Transforming growth factor-β; *TGFBR1*, Transforming growth factor-β receptor 1; *TGFBR2*, Transforming growth factor-β receptor 2; *BMP6*, Bone-morphogenetic protein 6; *PDGFBB*, Platelet-derived growth factor-bb; *COL1A1*; Collagen type 1, α1; *KDR*, Kinase domain receptor; *VEGFA*, Vascular endothelial growth factor A; *NOS3*, Endothelial nitric oxide synthase; *PECAM1*; Platelet endothelial cell adhesion molecule 1

Statistically significant with ANOVA compared to:
[a]T2DM no MVD vs. T2DM with CAD   [h]T2DM no MVD vs. T2DM with PAD
[b] T2DM with PAD vs. T2DM with CAD   [i]T2DM no MVD vs. T2DM with PAD
[c]T2DM no MVD vs. Healthy control   [j]T2DM no MVD vs. Healthy control
[d]T2DM no MVD vs. T2DM with CAD   [k]T2DM no MVD vs. Healthy control
[e]T2DM with PAD vs. T2DM with CAD   [l]T2DM no MVD vs. T2DM with CAD
[f]Healthy control vs. non-T2DM with CAD   [m]T2DM with CAD vs. T2DM with PAD
[g]non-T2DM with PAD vs. non-T2DM with CAD